The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Voyager Therapeutics Inc (NASDAQ: VYGR) closed the day trading at $4.72 up 0.85% from the previous closing price of $4.68. In other words, the price has increased by $0.85 from its previous closing price. On the day, 0.64 million shares were traded. VYGR stock price reached its highest trading level at $4.94 during the session, while it also had its lowest trading level at $4.7.
Ratios:
For a better understanding of VYGR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.43. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 18 ’25 when Ferguson Toby sold 19,000 shares for $3.73 per share. The transaction valued at 70,870 led to the insider holds 138,914 shares of the business.
Ferguson Toby bought 19,000 shares of VYGR for $70,680 on Aug 18 ’25. On Apr 02 ’25, another insider, Ferguson Toby, who serves as the Chief Medical Officer of the company, sold 10,086 shares for $3.43 each. As a result, the insider received 34,595 and left with 157,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 261812768 and an Enterprise Value of 86423768. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.15 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 2.03 whereas that against EBITDA is -0.727.
Stock Price History:
The Beta on a monthly basis for VYGR is 0.96, which has changed by -0.32954544 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $8.27, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is 24.98%, while the 200-Day Moving Average is calculated to be 19.22%.
Shares Statistics:
Over the past 3-months, VYGR traded about 744.01K shares per day on average, while over the past 10 days, VYGR traded about 787460 shares per day. A total of 55.43M shares are outstanding, with a floating share count of 45.49M. Insiders hold about 17.99% of the company’s shares, while institutions hold 60.05% stake in the company. Shares short for VYGR as of 1757894400 were 3140559 with a Short Ratio of 4.22, compared to 1755216000 on 2972876. Therefore, it implies a Short% of Shares Outstanding of 3140559 and a Short% of Float of 6.760000400000001.
Earnings Estimates
Its stock is currently analyzed by 10.0 different market analysts. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.34 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$1.41, with 10.0 analysts recommending between -$0.48 and -$2.64.
Revenue Estimates
12 analysts predict $7.86M in revenue for. The current quarter. It ranges from a high estimate of $12.5M to a low estimate of $5M. As of. The current estimate, Voyager Therapeutics Inc’s year-ago sales were $24.63MFor the next quarter, 12 analysts are estimating revenue of $10.54M. There is a high estimate of $23.4M for the next quarter, whereas the lowest estimate is $5M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $45.13M, while the lowest revenue estimate was $21.67M, resulting in an average revenue estimate of $30.08M. In the same quarter a year ago, actual revenue was $80MBased on 12 analysts’ estimates, the company’s revenue will be $62.29M in the next fiscal year. The high estimate is $145.95M and the low estimate is $8M.
